Event: Immuno Series UK 2020
Date: 24-25th August 2020
Immunitrack is proud to sponsor the annual Immuno Series UK event that brings together scientists and researchers who are at the leading edge of immune research from academia, biotech, and pharma, with the goal of developing new innovative immunotherapies.
Our agenda for the event: Throughout the entire event, you can view our on-demand technology showcase presentation by our CEO Stephan Thorgrimsen PhD. In addition, our CEO and CSO Sune Justesen PhD will host ad hoc webinar sessions about our T cell epitope screening platform. You can find out more about these by visiting our booth at any time during the conference.
Technology Showcase Presentation: A Unique Platform for T cell epitope screening for Immuno-Oncology Projects
The presentation will introduce our NeoScreen® platform for in vitro assessment of CD4 and CD8 T cell epitopes, and will examine various case studies. The case studies will include a HPV epitope T cell epitope screening project as well as a personalised cancer vaccine case where 32 neo-epitopes out of 20,000 cancer-specific mutations were selected for immunisation of a cancer patient.
Drop by our virtual booth during the event to learn more about Immunitrack and about how we can help you to select immunogenic cancer neo-epitopes for projects within immune-oncology, vaccine design or biologic development.
About The Event
The event is organised by Oxford Global. You can read more about the event on the organiser’s website here: Immuno Series UK Virtual Event 24-25th August 2020.
Immunitrack is founded upon world-leading academic research on MHC-epitope binding. Using our deep knowledge in this area, we have developed the proprietary epitope screening platform technology, NeoScreen®. NeoScreen® accurately assays the affinity and stability of MHC/epitope interactions, and the technology has the capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within immune-oncology, vaccine production, T cell therapies and immune monitoring.
Immunitrack’s mission is to provide the pharmaceutical industry and research community with technology and reagents to select or redesign drug candidates during early R&D and to monitor the effects of lead drug candidates on patient immune responses. Besides being a service provider, we are also a world-leading manufacturer and supplier of MHC tetramers.
Immunitrack actively collaborates with some of the leading research groups within immuno-oncology at the Johns Hopkins University Hospital, University of Columbia, Dana Farber Cancer Institute, and the National Center for Cancer Immune Therapy as well as leading pharmaceutical and biotech companies.